Eisai and Biogen launch Leqembi Iqlik autoinjector for at-home Alzheimer's treatment
New CapabilitiesSubcutaneous lecanemab is now available from the first dose, replacing a clinic-only infusion routine
Yesterday: IQLIK autoinjector launches in the USNew here? Follow stories to track developments over time. Create a free account to get updates when stories you care about change.
Overview
Updated 1 hour agoSince 2023 the Alzheimer's drug Leqembi came with a catch: patients needed intravenous infusions at a clinic every two weeks for 18 months. On August 24, Eisai and Biogen removed that hurdle, making a subcutaneous autoinjector version, LEQEMBI IQLIK, available from the very first dose.
The drug is the same — lecanemab, an antibody that clears amyloid plaques. What changed is delivery: two 15-second injections at home once a week replace a trip to the infusion center. That matters because roughly 80% of Leqembi patients need a caregiver to accompany them to those visits.
Why it matters
The biggest practical barrier to Alzheimer's treatment — clinic visits for infusions — just fell, opening the way for many more patients to start therapy.
Questions about this story
Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.
No questions yet — be the first to ask.
Key Indicators
Voices
Curated perspectives — historical figures and your fellow readers.
Play
Exploring all sides of a story is often best achieved with Play.
Higher or Lower
A number from this story, against one from elsewhere in the news — guess which is bigger, then keep the chain going. 5 rounds, 3 strikes; a miss costs a strike and resets your streak.
Keyboard: ↓/L lower · ↑/H higher
0 points — sign up to put that on the leaderboard.
Connections
Sixteen names from the news. Find the four hidden groups of four. Four mistakes max.
Sign up to keep a daily streak — a new puzzle lands every day.
Exit debate?
Your progress in this debate will be lost.
- 1 Two AI personas square off on this story.
- 2 You predict who'll win each round — correct picks earn XP.
- 3 One crossfire question is yours to fire. Pick it carefully.
Couldn't generate a topic
Select Your Champions
Choose one persona for each side of the debate
DEBATE TOPIC
Choose personas with different perspectives for a more dynamic debate.
Select debater for this side:
No debate personas available right now.
Select debater for this side:
No debate personas available right now.
Who's Got This Round?
Make your prediction before the referee scores
The referee scores both sides on
Round Results
Set the Crossfire
Pick the question both personas must answer in the final round
Debate Oracle! You called every round!
Sharp Instincts! You know your debaters!
The Coin Flip Strategist! Perfectly balanced!
The Contrarian! Bold predictions!
Inverse Genius! Try betting the opposite next time!
XP Breakdown
Prediction History
People Involved
Organizations Involved
Japanese drugmaker that developed and markets lecanemab, with Biogen co-marketing in the US.
US biotech co-marketing Leqembi and IQLIK with Eisai, sharing costs and profits.
Swedish firm that developed the antibody behind Leqembi and licensed it to Eisai.
Timeline
January 2023 August 2026
-
IQLIK autoinjector launches in the US
Latest LaunchEisai and Biogen make the at-home subcutaneous version available from the first dose for early Alzheimer's patients.
-
FDA approves IQLIK as an initiation dose
RegulatoryThe agency clears once-weekly subcutaneous lecanemab from the start of treatment, backed by exposure-equivalence data.
-
FDA approves IQLIK for maintenance dosing
RegulatoryThe autoinjector clears the agency for use after 18 months of IV or subcutaneous treatment.
-
FDA confirms Leqembi's benefit
RegulatoryThe agency converts accelerated approval to traditional approval after a confirmatory trial showed slower cognitive decline.
-
FDA approves Leqembi IV under accelerated approval
RegulatoryThe first anti-amyloid drug to win approval since Aduhelm, cleared for patients with early Alzheimer's.
Historical Context
3 moments from history that rhyme with this story — and how they unfolded.
Multiple sclerosis goes self-injected (2000s)
MS disease-modifying drugs, once given by infusion, moved to self-injected pens patients could use at home. This cut clinic visits dramatically and became the standard for a generation of patients.
Adherence and patient independence improved across the MS population.
It established the regulatory and usability framework for at-home biologic delivery in chronic neurologic disease.
Alzheimer's care is now following the same path, with elderly patients and caregivers managing treatment at home.
Herceptin moves from IV to subcutaneous (2013–2019)
Roche turned its breast cancer blockbuster Herceptin into a five-minute subcutaneous injection, approved in Europe in 2013 and the US in 2019. The shift cut administration time from roughly 90 minutes to minutes and let some patients get treatment at home.
Subcutaneous Herceptin captured a large share of the patient base in Europe within a few years.
It proved a major biologic could move from IV to home injection without losing efficacy, setting the template for drug delivery innovation.
IQLIK follows the same playbook for Alzheimer's — the identical drug molecule in a more convenient format.
Aduhelm's failed launch (2021–2024)
Biogen's first Alzheimer's antibody won accelerated approval in 2021 despite murky trial data and a controversial price. Medicare refused broad coverage, sales collapsed, and Biogen withdrew the drug, writing off billions.
Aduhelm's failure chilled the anti-amyloid market and shaped Medicare reimbursement decisions.
It raised the bar for proving benefit, pushing Leqembi toward a stricter trial design and more cautious rollout.
Leqembi's slow adoption after 2023 shows efficacy alone does not drive uptake — delivery logistics do. IQLIK targets that lesson directly.
